Mechanisms of bone metastasis in prostate cancer: clinical implications

被引:108
作者
Msaouel, Pavlos
Pissimissis, Nikos [1 ]
Halapas, Antonios
Koutsilieris, Michael [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Physiol, Goudi 11527, Greece
关键词
bone metastasis; cancer therapy; micrometastasis; prostate cancer; survival factors;
D O I
10.1016/j.beem.2008.01.011
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Prostate cancer shows a strong predilection to spread to the bones. Once prostate tumour cells are engrafted in the skeleton, curative therapy is no longer possible and palliative treatment becomes the only option. Herein, we review the multifactorial mechanisms and complex cellular interactions that take place inside the bone metastatic microenvironment. Emphasis is given to the detection and treatment of the micrometastatic stage of prostate cancer, as well as our recent attempts to target the bone metastasis microenvironment-related survival factors using an anti-survival factor manipulation which can increase the efficacy of anticancer therapies such as androgen ablation therapy and chemotherapy in advanced prostate cancer.
引用
收藏
页码:341 / 355
页数:15
相关论文
共 76 条
[1]
Recent advances in the detection of bone marrow micrometastases: A promising area for research or just another false hope? A review of the literature [J].
Athanassiadou, Pauline ;
Grapsa, Dimitra .
CANCER AND METASTASIS REVIEWS, 2006, 25 (04) :507-519
[2]
Batson O V, 1967, Prog Clin Cancer, V3, P1
[3]
LOSS OF HLA CLASS-I EXPRESSION IN PROSTATE-CANCER - IMPLICATIONS FOR IMMUNOTHERAPY [J].
BLADES, RA ;
KEATING, PJ ;
MCWILLIAM, LJ ;
GEORGE, NJR ;
STERN, PL .
UROLOGY, 1995, 46 (05) :681-686
[4]
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy [J].
Blute, ML ;
Bergstralh, EJ ;
Iocca, A ;
Scherer, B ;
Zincke, H .
JOURNAL OF UROLOGY, 2001, 165 (01) :119-125
[5]
Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton [J].
Bogdanos, J ;
Karamanolakis, D ;
Tenta, R ;
Tsintavis, A ;
Milathianakis, C ;
Mitsiades, C ;
Koutsilieris, M .
ENDOCRINE-RELATED CANCER, 2003, 10 (02) :279-289
[6]
Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].
Bubendorf, L ;
Schöpfer, A ;
Wagner, U ;
Sauter, G ;
Moch, H ;
Willi, N ;
Gasser, TC ;
Mihatsch, MJ .
HUMAN PATHOLOGY, 2000, 31 (05) :578-583
[7]
Mechanisms of disease: angiogenesis in urologic malignancies [J].
Charlesworth, PJS ;
Harris, AL .
NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (03) :157-169
[8]
A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines [J].
Chay, CH ;
Cooper, CR ;
Gendernalik, JD ;
Dhanasekaran, SM ;
Chinnaiyan, AM ;
Rubin, MA ;
Schmaier, AH ;
Pienta, KJ .
UROLOGY, 2002, 60 (05) :760-765
[9]
Long-term therapy with long-acting octreotide (Sandostatin-LAR®) for the management of acromegaly [J].
Davies, PH ;
Stewart, SE ;
Lancranjan, I ;
Sheppard, MC ;
Stewart, PM .
CLINICAL ENDOCRINOLOGY, 1998, 48 (03) :311-316
[10]
deCremoux P, 1997, EUR UROL, V32, P69